Literature DB >> 11400229

Prognostic significance of serum p53 protein and p53 antibody in patients with surgical treatment for head and neck squamous cell carcinoma.

V Chow1, A P Yuen, K Y Lam, W K Ho, W I Wei.   

Abstract

OBJECTIVES: This study aims at investigating the prognostic values of serum p53 protein and anti-p53 antibody in patients undergoing surgical treatment for head and neck squamous cell carcinoma (HNSCC).
METHODS: Serum p53 protein and anti-p53 antibody concentrations were determined by an enzyme-linked immunosorbent assay (ELISA) in 75 patients with HNSCC and 28 healthy controls. In 28 patients, formalin-fixed tumor tissues were also available for immunohistochemical staining by an anti-p53 DO7 monoclonal antibody. The results were correlated with the clinicopathologic parameters.
RESULTS: The mean preoperative serum concentration of p53 protein in patients with HNSCC was significantly higher than healthy controls (59.45 pg/mL vs 16.4 pg/mL, p =.007). Preoperative serum p53 antibody was present in 23 (31%) patients and was present in one healthy control. Eighteen (62%) tumor tissues showed p53 overexpression by immunohistochemistry. The presence of serum anti-p53 antibody before operation was associated with a significantly higher incidence (65%) of nodal metastasis compared with 27% nodal metastasis in patients with absence of serum anti-p53 antibody (p =.002).
CONCLUSION: Preoperative serum p53 antibody was a significant prognostic factor for nodal metastasis of HNSCC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11400229     DOI: 10.1002/hed.1032

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  13 in total

1.  Standards for immunohistochemical imaging: a protein reference device for biomarker quantitation.

Authors:  Donald H Atha; Upender Manne; William E Grizzle; Paul D Wagner; Sudhir Srivastava; Vytas Reipa
Journal:  J Histochem Cytochem       Date:  2010-08-30       Impact factor: 2.479

Review 2.  Immunotherapy for head and neck cancer: advances and deficiencies.

Authors:  Anna-Maria De Costa; M Rita I Young
Journal:  Anticancer Drugs       Date:  2011-08       Impact factor: 2.248

3.  Serum p53 and bladder cancer: can serum p53 be used as a tumor marker?

Authors:  Vibhav Malviya; Harbans Singh; U S Dwivedi; P B Singh
Journal:  Urol Res       Date:  2004-10-19

Review 4.  Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer.

Authors:  Aravind Suppiah; John Greenman
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

5.  Potential diagnostic value of serum p53 antibody for detecting esophageal cancer: a meta-analysis.

Authors:  Jun Zhang; Zhiwei Xv; Xuefeng Wu; Ke Li
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

6.  Predictive Role of p53 Protein as a Single Marker or Associated to Ki67 Antigen in Oral Carcinogenesis.

Authors:  L Montebugnoli; L Felicetti; D B Gissi; F Cervellati; D Servidio; C Marchetti; C Prati; F Flamminio; M P Foschini
Journal:  Open Dent J       Date:  2008-02-21

Review 7.  Molecular metastases markers in head and neck squamous cell carcinoma: review of the literature.

Authors:  G Cortesina; T Martone
Journal:  Acta Otorhinolaryngol Ital       Date:  2006-12       Impact factor: 2.124

8.  hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features.

Authors:  Alfred King-Yin Lam; Kate Ong; Yik-Hong Ho
Journal:  Int J Colorectal Dis       Date:  2008-03-06       Impact factor: 2.571

9.  A label-free biosensor based on silver nanoparticles array for clinical detection of serum p53 in head and neck squamous cell carcinoma.

Authors:  Wei Zhou; Yingyi Ma; Huan Yang; Yi Ding; Xiangang Luo
Journal:  Int J Nanomedicine       Date:  2011-03-02

10.  Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.

Authors:  Wei-Lei Yang; Aleksandra Gentry-Maharaj; Archana Simmons; Andy Ryan; Evangelia Ourania Fourkala; Zhen Lu; Keith A Baggerly; Yang Zhao; Karen H Lu; David Bowtell; Ian Jacobs; Steven J Skates; Wei-Wu He; Usha Menon; Robert C Bast
Journal:  Clin Cancer Res       Date:  2017-06-21       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.